Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Class Action Lawsuit Over Alleged Securities Fraud, Investors Report Financial Losses
Capricor Therapeutics Inc. is facing a class action lawsuit filed on behalf of investors who experienced financial losses due to alleged securities fraud. The lawsuit covers the period between October 9, 2024, and July 10, 2025, and claims that Capricor provided misleading information regarding the prospects of obtaining a Biologics License Application for its lead cell therapy candidate, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy. The U.S. Food and Drug Administration had issued a Complete Response Letter denying the BLA, citing insufficient evidence of effectiveness and outstanding issues related to Chemistry, Manufacturing, and Controls. Following this announcement, Capricor's stock price dropped significantly. The lawsuit alleges that the company failed to disclose material adverse facts about its Phase 2 HOPE-2 trial study, thereby misleading investors. The legal proceedings are being handled by Levi & Korsinsky, a firm with extensive experience in securities litigation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1073148) on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.